Related Experiment Videos
Bortezomib in combination with dexamethasone for relapsed multiple myeloma
Martin H Kropff1, Guido Bisping, Doris Wenning
1Department of Medicine/Hematology and Oncology, University of Münster, Albert-Schweitzer-Str. 33, 48149 Münster, Germany.
Abstract:
Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (> or = MR) of 80% (9/9 with > or = 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions